Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval
By Ben Glickman
Pharmaceutical regulators approved Amgen's Bkemv, a biosimilar to rare-disease treatment Soliris.
The Food and Drug Administration said Tuesday that Bkemv, a monoclonal antibody, had been approved for treating paroxysmal nocturnal hemoglobinuria, a rare blood disorder, and atypical hemolytic uremic syndrome, another rare disease affecting kidneys and blood-clotting.
Soliris, developed by AstraZeneca-owned Alexion Pharmaceuticals, is approved for the same treatment indications.
In patients with paroxysmal nocturnal hemoglobinuria, Bkemv is given to reduce hemolysis, while in treating atypical hemolytic uremic syndrome, the drug inhibits complement-mediated thrombotic microangiopathy.
The FDA said that Bkemv was the first interchangeable biosimilar to Soliris to treat the diseases.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
May 28, 2024 18:40 ET (22:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations